Myeloproliferative Neoplasms—Health Professional Version
Myeloproliferative neoplasms and myelodysplastic syndromes are diseases of the blood cells. They include chronic myeloproliferative neoplasms, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms. Find evidence-based information on myeloproliferative neoplasms treatment.
Myeloproliferative Neoplasms and Myelodysplastic Syndromes Treatment
-
Myelodysplastic Syndromes Treatment (PDQ®)
Myelodysplastic syndromes (MDS) treatment options include supportive care, disease-modifying agents, and allogeneic stem cell transplant. Get detailed information about the treatment of newly diagnosed and recurrent MDS in this summary for clinicians.
-
Myeloproliferative Neoplasms Treatment (PDQ®)
Myeloproliferative neoplasms (MPN) treatment varies widely depending on the specific diagnosis. Treatment options may include observation, phlebotomy, steroids, chemotherapy, immunotherapy, and stem cell transplant.
-
Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are treated with chemotherapy or other drugs, stem cell transplant, supportive care, and targeted therapy. Learn about the clinical features and treatment options for these conditions.
-
Childhood Acute Myeloid Leukemia Treatment (PDQ®)
Treatments for children with acute myeloid leukemia (AML) include combination chemotherapy, stem cell transplant, and targeted therapy. Other drug therapy and supportive care are also used. Get detailed information for AML in this clinician summary.
-
Drugs Approved for Myeloproliferative Neoplasms or Myelodysplastic Syndromes
This page lists cancer drugs approved by the Food and Drug Administration (FDA) for myeloproliferative neoplasms or myelodysplastic syndromes. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.
Clinical Trials
-
Treatment Clinical Trials for Myelodysplastic Syndrome
Find clinical trials for myelodysplastic syndrome treatment.
-
Treatment Clinical Trials for Chronic Myeloproliferative Disease
Find clinical trials for chronic myeloproliferative disease.
-
Treatment Clinical Trials for Myelodysplastic/ Myeloproliferative Disease
Find clinical trials for myelodysplastic/myeloproliferative disease.
Genetics Information
-
DDX41-Associated Myeloid Malignancies
DDX41-Associated Myeloid Malignancies is a hereditary hematologic malignancy syndrome associated with the DDX41 gene. Learn about DDX41's clinical features and management.
-
RUNX1-Familial Platelet Disorder
RUNX1-familial platelet disorder (RUNX1-FPD) is a hereditary hematologic malignancy syndrome associated with the RUNX1 gene. Learn about RUNX1-FPD’s clinical features and management.
-
GATA2 Deficiency Syndrome
GATA2 deficiency syndrome is a hereditary hematologic malignancy syndrome associated with the GATA2 gene. Learn about GATA2's clinical features and management.
-
Genetics of Hereditary Hematologic Malignancies
Genetics of Hereditary Hematologic Malignancies includes the hereditary cancer syndromes and genes associated with hematologic malignancies. Get comprehensive information about hereditary hematologic malignancies in this clinician summary.
Supportive & Palliative Care
-
Cancer Pain (PDQ®)
Get comprehensive, practical information on the screening, assessment, and management of cancer-related pain in this summary for clinicians.
-
Nausea and Vomiting Related to Cancer Treatment (PDQ®)
Get detailed information about prevention and treatment approaches for treatment-related nausea and vomiting in this summary for clinicians.
-
Nutrition in Cancer Care (PDQ®)
Get information about strategies to screen, assess, and treat nutritional problems, including through diet and supplements, in this clinician summary.
-
Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)
Planning the transition to end-of-life care in advanced cancer involves challenging decisions. Get information about strategies to improve patient-oncologist communication and decision making in this clinician summary.
-
Last Days of Life (PDQ®)
The last days of life for patients with cancer involves managing end-of-life (EOL) care issues for a wide range of possible symptoms and ethical dilemmas. Get detailed information about EOL issues and the role of the oncologist in this clinician summary.
-
Supportive and Palliative Care—PDQ® Cancer Information Summaries
The supportive and palliative care summaries provide descriptions of the pathophysiology and treatment of common physical and psychosocial complications of cancer and its treatment, such as pain, fatigue, and nausea/vomiting.